Traws Pharma (NASDAQ:TRAW – Get Free Report) was downgraded by research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research report issued on Monday, Marketbeat reports.
A number of other equities research analysts have also recently commented on TRAW. Weiss Ratings cut shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Citigroup cut shares of Traws Pharma to a “neutral” rating in a research note on Monday. Wall Street Zen raised shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Traws Pharma in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.00.
Get Our Latest Research Report on TRAW
Traws Pharma Price Performance
Traws Pharma (NASDAQ:TRAW – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39. Analysts anticipate that Traws Pharma will post -2.23 earnings per share for the current fiscal year.
Insider Activity
In other Traws Pharma news, major shareholder Orbimed Advisors Llc bought 597,729 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were purchased at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the transaction, the insider directly owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This represents a 98.71% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.57% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in TRAW. State Street Corp purchased a new position in shares of Traws Pharma during the 4th quarter valued at approximately $29,000. Two Sigma Investments LP lifted its position in shares of Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Traws Pharma by 294.2% in the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Traws Pharma in the fourth quarter valued at approximately $56,000. Finally, Geode Capital Management LLC lifted its position in shares of Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after acquiring an additional 18,213 shares in the last quarter. Hedge funds and other institutional investors own 7.95% of the company’s stock.
About Traws Pharma
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
Featured Articles
- Five stocks we like better than Traws Pharma
- Forget AI for a Moment, This Homebuilder Is Stealing the Show
- Qualcomm Drops 25%, But Investor Day Could Reverse the Slide
- Meta to Follow Alphabet’s Footsteps? What an Equity Raise Could Mean
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
